시장보고서
상품코드
1815630

세계의 약물감시 시장 보고서(2025년)

Pharmacovigilance Global Market Report 2025

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

약물감시 시장 규모는 향후 몇 년 동안 급격한 성장이 예상됩니다. 2029년에는 CAGR 12.6%로 155억 달러에 달할 전망입니다. 예측 기간의 성장은 의료비 지출 증가, 정부 지원 증가, 고령화 등에 기인합니다. 예측 기간의 주요 동향으로는 투자 증가, 인공지능 활용, 혁신적인 플랫폼 활용, 혁신적인 클라우드 기반 시스템 활용, 전략적 M&&A 등을 꼽을 수 있습니다.

향후 5년간 12.6%의 성장률 전망은 지난번 예측보다 0.3% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 장벽은 영국에 기반을 둔 공급자의 부작용 보고 시스템 및 신호 감지 소프트웨어의 비용을 상승시키고, 위험 평가를 지연시키며, 시판 후 조사 비용을 증가시킴으로써 의약품의 안전성 모니터링을 저해할 것으로 예측됩니다. 또한, 상호 관세와 무역 마찰 및 제한 강화로 인한 세계 경제 및 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

연구개발 활동의 활성화는 약물감시 시장을 촉진할 것으로 예측됩니다. 연구개발에 투자함으로써 제약기업은 안전성 프로파일을 강화한 혁신적인 신약을 개발할 수 있습니다. 의약품 개발 과정에서 엄격한 전임상 및 임상시험을 통해 잠재적인 안전성 문제를 조기에 파악하여 효과적인 위험 감소 전략을 실행할 수 있습니다. 또한, 연구개발 노력으로 부작용 모니터링, 데이터 분석, 신호 감지 기술이 발전하여 시판 후 부작용을 조기에 발견할 수 있게 되었습니다. 예를 들어, 2024년 2월 영국 기관인 Llywodraeth Cymru 웨일스 정부는 웨일스 정부가 2022년에 10억 파운드(12억 5,000만 달러)를 연구개발 사업비(BERD)에 투자하여 이 분야 영국 총 지출의 1.9%를 차지할 것이라고 보고했습니다. 이처럼 연구개발 활동의 성장이 파마코비즈니스 시장을 주도하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나19와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

  • 세계의 약물감시 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
  • 최종 이용 산업 분석
  • 세계의 약물감시 시장 : 성장률 분석
  • 세계의 약물감시 시장 실적 : 규모와 성장, 2019-2024
  • 세계의 약물감시 시장 예측 : 규모와 성장, 2024-2029, 2034F
  • 세계의 약물감시 : 총잠재 시장 규모(TAM)

제6장 시장 세분화

  • 세계의 약물감시 시장 : 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 자발적 보고
  • ADR 보고 강화
  • 표적화된 자발적 보고
  • 코호트 이벤트 모니터링
  • 전자의무기록(EHR) 마이닝
  • 세계의 약물감시 시장 서비스 : 제공업체별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 사내
  • 계약 아웃소싱
  • 세계의 약물감시 시장 : 프로세스 플로우별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 케이스 데이터 관리
  • 신호 감지
  • 리스크 관리 시스템
  • 세계의 약물감시 시장 : 임상시험 단계별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 전임상
  • 1상
  • 2상
  • 3상
  • 4상
  • 세계의 약물감시 시장 : 최종사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 병원
  • 제약회사
  • 기타 최종사용자
  • 세계의 약물감시 시장 : 자발적 보고(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 개별 증례 안전성 보고서(ICSR)
  • 자주 보고 시스템
  • 헬스케어 전문가로부터 증례 보고
  • 세계의 약물감시 시장 : ADR 보고 강화(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 적극적 감시 프로그램
  • 임상시험 내 강화된 모니터링
  • 위험 최소화 전략
  • 세계의 약물감시 시장 : 표적화된 자발적 보고(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 특정 약물 클래스에 대한 보고
  • 질환별 보고
  • 집중 감시 프로그램
  • 세계의 약물감시 시장 : 코호트 이벤트 모니터링(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 전향적 코호트 연구
  • 후향적 코호트 연구
  • 종단 연구
  • 세계의 약물감시 시장 : EHR 마이닝(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 전자건강기록에서의 데이터 추출
  • EHR 분석에 의한 신호 감지
  • EHR 데이터와 약물 감시 시스템 통합

제7장 지역별/국가별 분석

  • 세계의 약물감시 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
  • 세계의 약물감시 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

  • 약물감시 시장 : 경쟁 구도
  • 약물감시 시장 : 기업 개요
    • IQVIA : 개요, 제품 및 서비스, 전략 및 재무 분석
    • Cognizant : 개요, 제품 및 서비스, 전략 및 재무 분석
    • ICON Plc : 개요, 제품 및 서비스, 전략 및 재무 분석
    • Accenture plc : 개요, 제품 및 서비스, 전략 및 재무 분석
    • PAREXEL International Corporation. : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

  • United BioSource LLC
  • ArisGlobal
  • Quanticate
  • Wipro Limited
  • Linical Americas
  • Novotech CRO
  • Wuxi Apptec
  • Simcere Pharmaceutical Group
  • Lee's Pharmaceutical Holdings
  • Luye Pharma Group
  • EXTEDO
  • Arriello
  • PrimeVigilance
  • Axios International
  • C3i Solutions

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

  • 약물감시 시장(2029년) : 새로운 기회를 제공하는 국가
  • 약물감시 시장(2029년) : 새로운 기회를 제공하는 부문
  • 약물감시 시장(2029년) : 성장 전략
    • 시장 동향에 근거한 전략
    • 경쟁 전략

제36장 부록

LSH 25.09.25

Pharmacovigilance encompasses the science and practices dedicated to identifying, evaluating, understanding, and mitigating side effects and other medical/vaccination-related issues. Its purpose is to assess whether the benefits of a drug outweigh its risks, and this scrutiny persists even after drug approval.

The primary types of pharmacovigilance include spontaneous reporting, intensified adverse drug reaction (ADR) reporting, targeted spontaneous reporting, cohort event monitoring, and electronic health record (EHR) mining. Spontaneous reporting relies on individuals' voluntary reporting of suspected adverse drug reactions to local or national pharmacovigilance centers, representing a passive approach. Process flows involve case data management, signal detection, and risk management systems. Service providers can be in-house or contracted for outsourcing, covering various clinical trial phases such as preclinical, phase I, phase II, phase III, and phase IV. These services cater to different end-users, including hospitals, pharmaceutical companies, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The pharmacovigilance market research report is one of a series of new reports from The Business Research Company that provides pharmacovigilance market statistics, including pharmacovigilance industry global market size, regional shares, competitors with a pharmacovigilance market share, detailed pharmacovigilance market segments, market trends, and opportunities, and any further data you may need to thrive in the pharmacovigilance industry. This pharmacovigilance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pharmacovigilance market size has grown rapidly in recent years. It will grow from $8.58 billion in 2024 to $9.64 billion in 2025 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to the increasing incidence of adverse drug reactions (ADRs), the increasing research and development (R&D) activities, the growing drug development rates, the increasing focus on personalized medicine, and the rising prevalence of chronic diseases.

The pharmacovigilance market size is expected to see rapid growth in the next few years. It will grow to $15.5 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to the rising healthcare expenditure, the increasing government support and the aging population. Major trends in the forecast period include increasing investments, use of artificial intelligence, use of innovative platforms, use of innovative cloud-based systems, and strategic mergers and acquisitions.

The forecast of 12.6% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper drug safety monitoring by increasing the cost of adverse event reporting systems and signal detection software from UK-based providers, thereby delaying risk assessments and raising post-market surveillance costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rise in research and development activities is expected to propel the pharmacovigilance market. By investing in R&D, pharmaceutical companies can create new and innovative drugs with enhanced safety profiles. The rigorous preclinical and clinical testing during the drug development process allows for the early identification of potential safety issues, enabling the implementation of effective risk mitigation strategies. Furthermore, R&D efforts advance technologies for monitoring adverse events, data analysis, and signal detection, which facilitate the early identification of adverse drug reactions during the post-marketing phase. For example, in February 2024, the Llywodraeth Cymru Welsh Government, a UK-based agency, reported that Wales invested £1.0 billion ($1.25 billion) in Business Expenditure on Research and Development (BERD) in 2022, representing 1.9% of the total UK expenditure in this area. Thus, the growth in research and development activities is driving the pharmacovigilance market.

The increase in healthcare expenditure is expected to drive the growth of the pharmacovigilance market during the forecast period. With additional funding, healthcare systems can invest in advanced technologies, data analytics, and dedicated expert teams to effectively identify and assess adverse drug reactions. Moreover, greater healthcare spending facilitates better training and education for healthcare professionals on pharmacovigilance practices, ensuring timely reporting and analysis of potential drug-related issues. For example, in June 2024, The King's Fund, a UK-based non-profit organization, reported that the UK allocated 11.3% of its GDP to healthcare in 2022, slightly above the average for similar countries. This represents an increase from the pre-COVID-19 pandemic level of 9.9% of GDP dedicated to health services. This rise in expenditure underscores a growing emphasis on healthcare services in response to the pandemic, indicating a significant shift in funding priorities. Therefore, the increasing healthcare expenditure will support the growth of the pharmacovigilance market in the future.

Companies in the pharmacovigilance market are increasingly leveraging artificial intelligence (AI) to enhance efficiency. AI technology can significantly improve the accuracy and efficiency of pharmacovigilance activities, ultimately resulting in better patient outcomes. By incorporating AI, pharmaceutical companies can streamline processes, enhance data management, and expedite drug discovery, all while reducing costs and increasing safety. For example, in August 2024, the Government of India introduced the Adverse Drug Reaction Monitoring System (ADRMS) software, unveiled by the Minister of Health & Family Welfare and the Minister of Chemicals and Fertilizers. This pharmacovigilance software aids in the collection and analysis of adverse events related to medicines and medical devices, simplifying the reporting process for both consumers and healthcare professionals. This initiative considerably bolsters India's pharmacovigilance infrastructure by ensuring a more thorough capture of safety data and enhancing drug safety monitoring. The ADRMS aims to improve the efficiency of drug safety oversight and compliance with regulatory standards, positioning India as a leader in the global pharmaceutical industry.

Pharmacovigilance providers are making substantial investments to expand their product portfolios and geographic presence. In September 2022, the PharmaLex Group opened a new branch in Beijing, China, offering comprehensive pharmacovigilance, regulatory affairs, development advice, and quality management services to global companies entering the Chinese market. The PharmaLex Group's expansion aims to provide enhanced support and value across the product lifecycle.

In January 2023, AmerisourceBergen acquired Pharma Lex to augment its existing service offering and provide pharmaceutical and biotech companies with comprehensive support for pharmacovigilance systems and operations, including benefit-risk management services. These strategic investments contribute to the growth and expansion of the pharmacovigilance market.

Major companies operating in the pharmacovigilance market include IQVIA, Cognizant, ICON Plc, Accenture plc, PAREXEL International Corporation., United BioSource LLC, ArisGlobal, Quanticate, Wipro Limited, Linical Americas, Novotech CRO, Wuxi Apptec, Simcere Pharmaceutical Group, Lee's Pharmaceutical Holdings, Luye Pharma Group, EXTEDO, Arriello, PrimeVigilance, Axios International, C3i Solutions, Alcon, Secure AI Labs, OmniSol dot Tech, Canna Call Company, Veripad, Prevnos Inc., Lifescient, Inc, BeiGene, QuintilesIMS, Labcorp Drug Development, Pharmaceutical Product Development Inc., PRA Health Sciences, Synowledge LLC, RAPAhub, illuminate health, Invenio Medical, ClinChoice Inc., MSD, Novasyte, Fortrea Holdings Inc, Syneos Health Clinical, Zoetis Inc., Telerx Marketing Inc., Gilead Sciences, Inc., Elanco, Abbott Laboratories, Spimaco, Teva Pharmaceutical Industries Ltd.

North America was the largest region in the pharmacovigilance market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast region. The regions covered in the pharmacovigilance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the pharmacovigilance market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The pharmacovigilance market includes revenues earned by collecting, analyzing, monitoring, and preventing adverse effects in drugs and therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pharmacovigilance Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pharmacovigilance market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pharmacovigilance ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pharmacovigilance market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining
  • 2) By Service Provider: In-House, Contract Outsourcing
  • 3) By Process Flow: Case Data Management, Signal Detection, Risk Management System
  • 4) By Clinical Trial Phases: Preclinical, Phase I, Phase II, Phase III, Phase IV
  • 5) By End User: Hospitals, Pharmaceutical Companies, Other End Users
  • Subsegments:
  • 1) By Spontaneous Reporting: Individual Case Safety Reports (ICSRs); Voluntary Reporting Systems; Case Reports From Healthcare Professionals
  • 2) By Intensified ADR Reporting: Active Surveillance Programs; Enhanced Monitoring In Clinical Trials; Risk Minimization Strategies
  • 3) By Targeted Spontaneous Reporting: Reporting For Specific Drug Classes; Condition-Specific Reporting; Focused Surveillance Programs
  • 4) By Cohort Event Monitoring: Prospective Cohort Studies; Retrospective Cohort Studies; Longitudinal Studies
  • 5) By EHR Mining: Data Extraction From Electronic Health Records; Signal Detection Through EHR Analysis; Integration Of EHR Data With Pharmacovigilance Systems
  • Companies Mentioned: IQVIA; Cognizant; ICON Plc; Accenture plc; PAREXEL International Corporation.; United BioSource LLC; ArisGlobal; Quanticate; Wipro Limited; Linical Americas; Novotech CRO; Wuxi Apptec; Simcere Pharmaceutical Group; Lee's Pharmaceutical Holdings; Luye Pharma Group; EXTEDO; Arriello; PrimeVigilance; Axios International; C3i Solutions; Alcon; Secure AI Labs; OmniSol dot Tech; Canna Call Company; Veripad; Prevnos Inc.; Lifescient, Inc; BeiGene; QuintilesIMS; Labcorp Drug Development; Pharmaceutical Product Development Inc.; PRA Health Sciences; Synowledge LLC; RAPAhub; illuminate health; Invenio Medical; ClinChoice Inc.; MSD; Novasyte; Fortrea Holdings Inc; Syneos Health Clinical; Zoetis Inc.; Telerx Marketing Inc.; Gilead Sciences, Inc.; Elanco; Abbott Laboratories; Spimaco; Teva Pharmaceutical Industries Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pharmacovigilance Market Characteristics

3. Pharmacovigilance Market Trends And Strategies

4. Pharmacovigilance Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Pharmacovigilance Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Pharmacovigilance PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Pharmacovigilance Market Growth Rate Analysis
  • 5.4. Global Pharmacovigilance Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Pharmacovigilance Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Pharmacovigilance Total Addressable Market (TAM)

6. Pharmacovigilance Market Segmentation

  • 6.1. Global Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining
  • 6.2. Global Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • In-House
  • Contract Outsourcing
  • 6.3. Global Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Case Data Management
  • Signal Detection
  • Risk Management System
  • 6.4. Global Pharmacovigilance Market, Segmentation By Clinical Trial Phases, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • 6.5. Global Pharmacovigilance Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Pharmaceutical Companies
  • Other End Users
  • 6.6. Global Pharmacovigilance Market, Sub-Segmentation Of Spontaneous Reporting, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Individual Case Safety Reports (ICSRs)
  • Voluntary Reporting Systems
  • Case Reports From Healthcare Professionals
  • 6.7. Global Pharmacovigilance Market, Sub-Segmentation Of Intensified ADR Reporting, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Active Surveillance Programs
  • Enhanced Monitoring In Clinical Trials
  • Risk Minimization Strategies
  • 6.8. Global Pharmacovigilance Market, Sub-Segmentation Of Targeted Spontaneous Reporting, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Reporting For Specific Drug Classes
  • Condition-Specific Reporting
  • Focused Surveillance Programs
  • 6.9. Global Pharmacovigilance Market, Sub-Segmentation Of Cohort Event Monitoring, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Prospective Cohort Studies
  • Retrospective Cohort Studies
  • Longitudinal Studies
  • 6.10. Global Pharmacovigilance Market, Sub-Segmentation Of EHR Mining, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Data Extraction From Electronic Health Records
  • Signal Detection Through EHR Analysis
  • Integration Of EHR Data With Pharmacovigilance Systems

7. Pharmacovigilance Market Regional And Country Analysis

  • 7.1. Global Pharmacovigilance Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Pharmacovigilance Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pharmacovigilance Market

  • 8.1. Asia-Pacific Pharmacovigilance Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pharmacovigilance Market

  • 9.1. China Pharmacovigilance Market Overview
  • 9.2. China Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pharmacovigilance Market

  • 10.1. India Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pharmacovigilance Market

  • 11.1. Japan Pharmacovigilance Market Overview
  • 11.2. Japan Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pharmacovigilance Market

  • 12.1. Australia Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pharmacovigilance Market

  • 13.1. Indonesia Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pharmacovigilance Market

  • 14.1. South Korea Pharmacovigilance Market Overview
  • 14.2. South Korea Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pharmacovigilance Market

  • 15.1. Western Europe Pharmacovigilance Market Overview
  • 15.2. Western Europe Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pharmacovigilance Market

  • 16.1. UK Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pharmacovigilance Market

  • 17.1. Germany Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pharmacovigilance Market

  • 18.1. France Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pharmacovigilance Market

  • 19.1. Italy Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pharmacovigilance Market

  • 20.1. Spain Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pharmacovigilance Market

  • 21.1. Eastern Europe Pharmacovigilance Market Overview
  • 21.2. Eastern Europe Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pharmacovigilance Market

  • 22.1. Russia Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pharmacovigilance Market

  • 23.1. North America Pharmacovigilance Market Overview
  • 23.2. North America Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pharmacovigilance Market

  • 24.1. USA Pharmacovigilance Market Overview
  • 24.2. USA Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pharmacovigilance Market

  • 25.1. Canada Pharmacovigilance Market Overview
  • 25.2. Canada Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pharmacovigilance Market

  • 26.1. South America Pharmacovigilance Market Overview
  • 26.2. South America Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pharmacovigilance Market

  • 27.1. Brazil Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pharmacovigilance Market

  • 28.1. Middle East Pharmacovigilance Market Overview
  • 28.2. Middle East Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pharmacovigilance Market

  • 29.1. Africa Pharmacovigilance Market Overview
  • 29.2. Africa Pharmacovigilance Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Pharmacovigilance Market, Segmentation By Service Provider, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Pharmacovigilance Market, Segmentation By Process Flow, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pharmacovigilance Market Competitive Landscape And Company Profiles

  • 30.1. Pharmacovigilance Market Competitive Landscape
  • 30.2. Pharmacovigilance Market Company Profiles
    • 30.2.1. IQVIA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Cognizant Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. ICON Plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Accenture plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. PAREXEL International Corporation. Overview, Products and Services, Strategy and Financial Analysis

31. Pharmacovigilance Market Other Major And Innovative Companies

  • 31.1. United BioSource LLC
  • 31.2. ArisGlobal
  • 31.3. Quanticate
  • 31.4. Wipro Limited
  • 31.5. Linical Americas
  • 31.6. Novotech CRO
  • 31.7. Wuxi Apptec
  • 31.8. Simcere Pharmaceutical Group
  • 31.9. Lee's Pharmaceutical Holdings
  • 31.10. Luye Pharma Group
  • 31.11. EXTEDO
  • 31.12. Arriello
  • 31.13. PrimeVigilance
  • 31.14. Axios International
  • 31.15. C3i Solutions

32. Global Pharmacovigilance Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pharmacovigilance Market

34. Recent Developments In The Pharmacovigilance Market

35. Pharmacovigilance Market High Potential Countries, Segments and Strategies

  • 35.1 Pharmacovigilance Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Pharmacovigilance Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Pharmacovigilance Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제